Clinical Trial Update: Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation [Phase 1]

View source ↗

Summary

Phase 1 trial update reporting completion of a study evaluating ultra-low-dose interleukin-2 as graft-versus-host disease prophylaxis in haploidentical allogene…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Interleukin-2 (Aldesleukin) (aldesleukin)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML) | Phase 1 | Status: COMPLETED